Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy
B Van Den Blink, MR Dillingh, LC Ginns… - European …, 2016 - Eur Respiratory Soc
B Van Den Blink, MR Dillingh, LC Ginns, LD Morrison, M Moerland, M Wijsenbeek…
European Respiratory Journal, 2016•Eur Respiratory SocAbnormal fibrogenic repair response upon alveolar injury is believed to play an important
role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). PRM-151 (recombinant
human pentraxin-2, also known as serum amyloid P), has been shown to reduce fibrosis in
preclinical lung fibrosis models, and was well tolerated with a favourable pharmacokinetic
profile in an earlier single-dose phase I study. A randomised, double-blind, placebo-
controlled, multiple ascending dose trial was performed to assess the tolerability and …
role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). PRM-151 (recombinant
human pentraxin-2, also known as serum amyloid P), has been shown to reduce fibrosis in
preclinical lung fibrosis models, and was well tolerated with a favourable pharmacokinetic
profile in an earlier single-dose phase I study. A randomised, double-blind, placebo-
controlled, multiple ascending dose trial was performed to assess the tolerability and …
Abnormal fibrogenic repair response upon alveolar injury is believed to play an important role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). PRM-151 (recombinant human pentraxin-2, also known as serum amyloid P), has been shown to reduce fibrosis in preclinical lung fibrosis models, and was well tolerated with a favourable pharmacokinetic profile in an earlier single-dose phase I study.
A randomised, double-blind, placebo-controlled, multiple ascending dose trial was performed to assess the tolerability and pharmacokinetic and pharmacodynamic characteristics of multiple doses of PRM-151 in IPF patients. Subjects in three successive cohorts (1, 5, or 10 mg·kg−1 versus placebo) received intravenous study drug on days 1, 3, 5, 8 and 15, and were followed-up to day 57.
PRM-151 was well tolerated at all dose levels, with no serious adverse reactions. Administration of PRM-151 resulted in two- to eight-fold dose-dependent increases in circulating pentraxin-2 levels. Forced vital capacity and 6-min walk test showed trends towards improvement in the combined PRM-151 dose groups. On high-resolution computed tomography scans, stable or improved lung volume unoccupied by interstitial lung abnormality was noted in some PRM-151 subjects compared to placebo subjects on day 57.
The efficacy of PRM-151 in IPF remains to be investigated in dedicated future trials.
European Respiratory Society